GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival

Cancer

Volumn 120, Issue 9, 2014, Pages 1329-1337

  Jiang, Yi Zhou ^a   Yu, Ke Da ^a   Zuo, Wen Jia ^a   Peng, Wen Ting ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

breast cancer; GATA binding protein 3; luminal like subtype; prognosis; somatic mutation

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GATA3 GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

BREAST CANCER; GATA BINDING PROTEIN 3; LUMINAL-LIKE SUBTYPE; PROGNOSIS; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; MIDDLE AGED; MUTATION; POSTMENOPAUSE; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84899475944     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28566     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486: 395-399.
3. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486: 400-404.
4. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486: 353-360.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
6. Simon MC,. Gotta have GATA. Nat Genet. 1995; 11: 9-11.
7. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z,. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell. 2006; 127: 1041-1055.
8. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol. 2007; 9: 201-209.
9. Ho IC, Tai TS, Pai SY,. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 2009; 9: 125-135.
10. Mehra R, Varambally S, Ding L, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005; 65: 11259-11264.
11. Yoon NK, Maresh EL, Shen D, et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol. 2010; 41: 1794-1801.
12. Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP,. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol. 2009; 40: 489-495.
13. Yu KD, Zhu R, Zhan M, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013; 19: 2723-2733.
14. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28: 3271-3277.
15. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H,. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28: 1684-1691.
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ,. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747.
17. Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res. 2013; 19: 3285-3296.
18. Yu KD, Huang AJ, Fan L, Li WF, Shao ZM,. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res. 2012; 72: 408-419.
19. Usary J, Llaca V, Karaca G, et al. Mutation of GATA3 in human breast tumors. Oncogene. 2004; 23: 7669-7678.
20. Arnold JM, Choong DY, Thompson ER, et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2010; 119: 491-496.
21. Yang Z, Gu L, Romeo PH, et al. Human GATA-3 trans-activation, DNA-binding, and nuclear localization activities are organized into distinct structural domains. Mol Cell Biol. 1994; 14: 2201-2212.
22. Nesbit MA, Bowl MR, Harding B, et al. Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome. J Biol Chem. 2004; 279: 22624-22634.
23. Ali A, Christie PT, Grigorieva IV, et al. Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Hum Mol Genet. 2007; 16: 265-275.
24. Buron N, Guery L, Creuzot-Garcher C, et al. Trefoil factor TFF1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels. Invest Ophthalmol Vis Sci. 2008; 49: 3790-3798.
25. Vie N, Copois V, Bascoul-Mollevi C, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008; 7: 14.
26. Brychtova V, Vojtesek B, Hrstka R,. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 2011; 304: 1-7.
27. Kastl L, Brown I, Schofield AC,. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012; 131: 445-454.
28. Molenaar JJ, Ebus ME, Koster J, et al. Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene. 2010; 29: 2739-2745.